288 related articles for article (PubMed ID: 30361845)
1. Nivolumab-induced fulminant type 1 diabetes (T1D): the first Italian case report with long follow-up and flash glucose monitoring.
Tassone F; Colantonio I; Gamarra E; Gianotti L; Baffoni C; Magro G; Borretta G
Acta Diabetol; 2019 Apr; 56(4):489-490. PubMed ID: 30361845
[No Abstract] [Full Text] [Related]
2. Nivolumab-induced fulminant type 1 diabetes with precipitous fall in C-peptide level.
Miyauchi M; Toyoda M; Zhang J; Hamada N; Yamawaki T; Tanaka J; Harada K; Kashizaki F; Fukagawa M
J Diabetes Investig; 2020 May; 11(3):748-749. PubMed ID: 31587459
[TBL] [Abstract][Full Text] [Related]
3. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.
Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R
J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767
[No Abstract] [Full Text] [Related]
4. Two cases with fulminant type 1 diabetes that developed long after cessation of immune checkpoint inhibitor treatment.
Hatayama S; Kodama S; Kawana Y; Otake S; Sato D; Horiuchi T; Takahashi K; Kaneko K; Imai J; Katagiri H
J Diabetes Investig; 2022 Aug; 13(8):1458-1460. PubMed ID: 35396830
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab-induced acute-onset type 1 diabetes mellitus as an immune-related adverse event: A case report.
Hatakeyama Y; Ohnishi H; Suda K; Okamura K; Shimada T; Yoshimura S
J Oncol Pharm Pract; 2019 Dec; 25(8):2023-2026. PubMed ID: 30526346
[TBL] [Abstract][Full Text] [Related]
6. Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer.
Kuraoka N; Hara K; Terai S; Yatabe Y; Horio Y
Endoscopy; 2018 Sep; 50(9):E259-E261. PubMed ID: 29969801
[No Abstract] [Full Text] [Related]
7. A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia.
Yamamoto N; Tsurutani Y; Katsuragawa S; Kubo H; Sunouchi T; Hirose R; Hoshino Y; Ichikawa M; Takiguchi T; Yukawa H; Arioka H; Saitou J; Nishikawa T
Intern Med; 2019 Oct; 58(19):2825-2830. PubMed ID: 31243198
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma.
Mazzaschi G; Bordi P; Fioretzaki R; Gnetti L; Milanese G; Tommasi C; Bersanelli M; Roti G; Scoditti U; Leonardi F; Quaini F; Tiseo M
Clin Lung Cancer; 2020 Mar; 21(2):e65-e73. PubMed ID: 31837925
[No Abstract] [Full Text] [Related]
9. Feasibility of FreeStyle Libre Flash Glucose Monitoring System in pregnant woman affected by type 1 diabetes.
Gatti M
Acta Diabetol; 2019 Apr; 56(4):481-483. PubMed ID: 30415324
[No Abstract] [Full Text] [Related]
10. Flash Glucose Monitoring Improves Outcomes in a Type 1 Diabetes Clinic.
Dover AR; Stimson RH; Zammitt NN; Gibb FW
J Diabetes Sci Technol; 2017 Mar; 11(2):442-443. PubMed ID: 27464754
[No Abstract] [Full Text] [Related]
11. Barriers to Glucose Testing and Attitudes Toward Mobile App and Device Use in a Large Cohort of T1D Pediatric Patients: Implications for Diabetes Management.
Barnes TL; Lee S; Thompson N; Mullen K; Chatterton P; Gandrud L
J Diabetes Sci Technol; 2018 Nov; 12(6):1246-1247. PubMed ID: 30136595
[No Abstract] [Full Text] [Related]
12. Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?
Marchand L; Reffet S; Dalle S; Disse E; Vouillarmet J; Cugnet-Anceau C; Thivolet C
Acta Diabetol; 2019 Mar; 56(3):377-378. PubMed ID: 30506459
[No Abstract] [Full Text] [Related]
13. Accuracy Evaluation of a New System for Self-Monitoring of Blood Glucose With Three Test Strip Lots Based on ISO 15197:2013.
Baumstark A; Jendrike N; Pleus S; Liebing C; Haug C; Freckmann G
J Diabetes Sci Technol; 2018 Mar; 12(2):539-540. PubMed ID: 28931322
[No Abstract] [Full Text] [Related]
14. Glucose Variations During Driving in People With Type 1 Diabetes Using a Continuous Glucose Monitoring System.
Schmied LS; Zulewski H
Diabetes Care; 2019 Jul; 42(7):1340-1343. PubMed ID: 31221699
[TBL] [Abstract][Full Text] [Related]
15. Self-care for the young diabetic--home but not alone.
Chase HP; Chase VC; Garg SK
Contemp Pediatr; 1991 Sep; 8(Special Issue):74-88. PubMed ID: 10148045
[No Abstract] [Full Text] [Related]
16. Fulminant type 1 diabetes associated with nivolumab in a patient with metastatic melanoma.
Takahashi A; Tsutsumida A; Namikawa K; Yamazaki N
Melanoma Res; 2018 Apr; 28(2):159-160. PubMed ID: 29485550
[No Abstract] [Full Text] [Related]
17. Atmospheric pressure effects on glucose monitoring devices.
Piepmeier EH; Hammett-Stabler C; Price ME; Kemper GB; Davis MG
Diabetes Care; 1995 Mar; 18(3):423-4. PubMed ID: 7555495
[No Abstract] [Full Text] [Related]
18. Talking glucose meter for the visually impaired diabetic patient: the effect of haematocrit on glucose measurement.
Peake RW; Devgun MS; O'Brien IA
Br J Biomed Sci; 2012; 69(1):41-2. PubMed ID: 22558807
[No Abstract] [Full Text] [Related]
19. The Hormone Foundation's: Patient guide to continuous glucose monitoring.
Tamborlane WV; Vigersky RA
J Clin Endocrinol Metab; 2011 Oct; 96(10):29A-30A. PubMed ID: 21976752
[No Abstract] [Full Text] [Related]
20. Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis.
Ide M; Tanaka K; Sunami S; Asoh T; Maeyama T; Tsuruta N; Nakanishi Y; Okamoto I
Thorac Cancer; 2018 Nov; 9(11):1519-1521. PubMed ID: 30152594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
